ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that four abstracts on TRU-016 have been accepted for presentation at the 53rd Annual Meeting of the American Society of Hematology (ASH) on December 10-13, 2011 in San Diego, California. The data accepted for presentation include clinical results from a Phase 1 study evaluating patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL). TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is being developed in collaboration with Abbott.
